Advertisement

Clinical outcome of nivolumab in older and frail patients with recurrent/metastatic head and neck squamous cell carcinoma

Published:September 27, 2022DOI:https://doi.org/10.1016/j.jgo.2022.09.009
      It is expected, by 2030, that about 65% of head and neck squamous cell carcinoma (HNSCC) will affect people aged over 65 years [
      • Smith B.D.
      • Smith G.L.
      • Hurria A.
      • Hortobagyi G.N.
      • Buchholz T.A.
      Future of cancer incidence in the United States: burdens upon an aging, changing nation.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Smith B.D.
        • Smith G.L.
        • Hurria A.
        • Hortobagyi G.N.
        • Buchholz T.A.
        Future of cancer incidence in the United States: burdens upon an aging, changing nation.
        J Clin Oncol. 2009; 27: 2758-2765https://doi.org/10.1200/JCO.2008.20.8983
        • Burtness B.
        • Harrington K.J.
        • Greil R.
        • Soulières D.
        • Tahara M.
        • de Castro G.
        • et al.
        Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
        Lancet. 2019; 394: 1915-1928https://doi.org/10.1016/S0140-6736(19)32591-7
        • Vermorken J.B.
        • Mesia R.
        • Rivera F.
        • Remenar E.
        • Kawecki A.
        • Rottey S.
        • et al.
        Platinum-based chemotherapy plus cetuximab in head and neck cancer.
        N Engl J Med. 2008; 359: 1116-1127https://doi.org/10.1056/NEJMoa0802656
        • Ferris R.L.
        • Blumenschein Jr., G.
        • Fayette J.
        • Guigay J.
        • Colevas A.D.
        • Licitra L.
        • et al.
        Nivolumab for recurrent squamous-cell carcinoma of the head and neck.
        N Engl J Med. 2016; 375: 1856-1867https://doi.org/10.1056/NEJMoa1602252
        • Welaya K.
        • Loh K.P.
        • Messing S.
        • Szuba E.
        • Magnuson A.
        • Mohile S.G.
        • et al.
        Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors.
        J Geriatr Oncol. 2020; 11: 523-528https://doi.org/10.1016/j.jgo.2019.05.021
        • Takahashi M.
        • Takahashi M.
        • Komine K.
        • Yamada H.
        • Kasahara Y.
        • Chikamatsu S.
        • et al.
        The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: a retrospective, single institutional study.
        PLoS One. 2017; 12e0179694https://doi.org/10.1371/journal.pone.0179694
        • Gogineni E.
        • Rana Z.
        • Wotman M.
        • Karten J.
        • Riegel A.
        • Marrero M.
        • et al.
        Impact of stereotactic body radiation therapy on geriatric assessment and management for older patients with head and neck cancer using G8.
        J Geriatr Oncol. 2021; 12: 122-127https://doi.org/10.1016/j.jgo.2020.06.023
        • Nebhan C.A.
        • Cortellini A.
        • Ma W.
        • Ganta T.
        • Song H.
        • Ye F.
        • et al.
        Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study.
        JAMA Oncol. 2021; 7: 1856-1861https://doi.org/10.1001/jamaoncol.2021.4960
        • Hurez V.
        • Padrón Á.S.
        • Svatek R.S.
        • Curiel T.J.
        Considerations for successful cancer immunotherapy in aged hosts.
        Clin Exp Immunol. 2017; 187: 53-63https://doi.org/10.1111/cei.12875
        • Chan T.A.
        • Yarchoan M.
        • Jaffee E.
        • Swanton C.
        • Quezada S.A.
        • Stenzinger A.
        • et al.
        Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
        Ann Oncol. 2019; 30: 44-56https://doi.org/10.1093/annonc/mdy495
        • Mountzios G.
        Optimal management of the elderly patient with head and neck cancer: issues regarding surgery, irradiation and chemotherapy.
        World J Clin Oncol. 2015; 6: 7-15https://doi.org/10.5306/wjco.v6.i1.7
        • Mohile S.G.
        • Dale W.
        • Somerfield M.R.
        • Schonberg M.A.
        • Boyd C.M.
        • Burhenn P.S.
        • et al.
        Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology.
        J Clin Oncol. 2018; 36: 2326-2347https://doi.org/10.1200/JCO.2018.78.8687
        • Mohile S.G.
        • Mohamed M.R.
        • Xu H.
        • Culakova E.
        • Loh K.P.
        • Magnuson A.
        • et al.
        Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.
        Lancet. 2021; 398: 1894-1904https://doi.org/10.1016/S0140-6736(21)01789-X
        • Ramnaraign B.H.
        • Chatzkel J.A.
        • Al-Mansour Z.A.
        • Rogers S.
        • Jones D.
        • DeRemer D.
        • et al.
        Immunotherapy Management in Special Cancer Patient Populations.
        JCO Oncol Pract. 2021; 17: 240-245https://doi.org/10.1200/OP.20.00996